B. Riley Securities Rates Elicio Therapeutics (ELTX) buy
B. Riley Securities maintains its buy rating on Elicio Therapeutics with a $27 price target, a 561.76% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
B. Riley Securities rated Elicio Therapeutics, Inc. ($ELTX) "buy" with a $27 price target on June 10, 2026.
Since the rating, $ELTX is down 67.1% after 1 week, down 75.7% after 1 month and down 89.1% to date (from the $14.30 close on Jun 10, 2026).
ELTX
Elicio Therapeutics, Inc.
Key Points
- B. Riley Securities reiterated its buy rating for Elicio Therapeutics on June 10, 2026, with a $27 price target.
- B. Riley Securities's $27 price target implies 561.76% upside from Elicio Therapeutics, Inc.'s ($ELTX) current $4.08 share price.
- Elicio Therapeutics, trading at $14.85, focuses on cancer immunotherapies and has a market cap of $283 million.
- Institutional investors like Renaissance Technologies and Vanguard Capital have adjusted their positions in ELTX.
Get $ELTX trade alerts by text
We text you when insiders, Congress or big funds trade $ELTX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Elicio Therapeutics, Inc. alert may contain errors. Disclosures
B. Riley Securities reiterated its buy rating for Elicio Therapeutics, Inc. (NasdaqCM: ELTX) on June 10, 2026, setting a price target of $27. Shares of Elicio are currently trading at $14.85. This update reflects the firm's confidence in the company's prospects.
Other Institutional Activity in Elicio Therapeutics
Several institutional investors have made recent moves in Elicio Therapeutics. Renaissance Technologies LLC significantly boosted its position by 93,520 shares, ending with 121,631 shares valued at approximately $1.3 million. Vanguard Capital Management LLC initiated a new position with 518,638 shares worth about $5.5 million. Meanwhile, Balyasny Asset Management L.P. increased its holdings by 106,052 shares, bringing its total to 244,814 shares valued at around $2.6 million.
Elicio Therapeutics, Inc. Stock Up 115.9%
Shares of Elicio Therapeutics (NasdaqCM: ELTX) are currently priced at $14.85. The company, with a market cap of about $283 million, is not yet profitable, reflected by its lack of a meaningful P/E ratio. Over the past 52 weeks, the stock has ranged from $7.37 to $16.00. It has a 50-day moving average of $11.37 and a 200-day moving average of $10.07. The company's financial health is supported by a current ratio of 2.24 and a quick ratio of 2.07.
$ELTX price target
Elicio Therapeutics, Inc. daily closes and this analyst's $27 target. Not advice.
Insider Buying and Selling at Elicio Therapeutics, Inc.
Several insiders at Elicio Therapeutics have recently acquired shares. On February 2, 2026, CEO Robert Connelly purchased 147,200 shares. Other executives, including Christopher Haqq, Peter Demuth, and Preetam Shah, also bought shares on the same day, with Demuth acquiring a total of 41,600 shares.
Analysts Set New Price Targets
On June 10, 2026, B. Riley Securities reiterated its buy rating for Elicio Therapeutics with a $27 price target. Earlier, on April 15, 2026, Ladenburg Thalmann initiated coverage with a buy rating and a $20 target. HC Wainwright & Co. maintained its buy rating on March 13, 2026, with a target of $17. The consensus among analysts is a strong buy, with an average target price of approximately $20.67 based on three opinions.
About Elicio Therapeutics
Elicio Therapeutics, Inc. is a biotechnology company based in Boston, Massachusetts. It focuses on developing immunotherapies for cancer treatment. The company's lead product, ELI-002, is in Phase II trials targeting Kirsten rat sarcoma viral oncogene homolog mutations. Elicio is also working on treatments for BRAF-driven cancers and mutated p53-expressing cancers. Led by CEO Robert T. Connelly, the company employs 33 people.
Bottom Line
B. Riley Securities' reiterated buy rating and $27 target for Elicio Therapeutics underscores confidence in the company's future. Investors and analysts alike are closely watching Elicio's progress in developing cancer immunotherapies. Remember, analyst ratings are one of many tools investors use to make informed decisions.
Related Filing Alerts
Source: B. Riley Securities's rating change on $ELTX (Jun 10, 2026). Written by software, not financial advice. How we make alerts